Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies

Kebede Hussein; Rhett P. Ketterling; Gordon W. Dewald; Daniel L. Van Dyke; Ruben Mesa; Curtis A. Hanson; Ayalew Tefferi

doi:10.1016/j.leukres.2007.12.005

Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies

Kebede Hussein, Rhett P. Ketterling, Gordon W. Dewald, Daniel L. Van Dyke, Ruben Mesa, Curtis A. Hanson, Ayalew Tefferi

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Among 59 consecutive patients with myelofibrosis (MF) in whom peripheral blood (PB) cytogenetic studies were performed, at least two analyzable metaphases (median 20, range 2-31) were obtained in 49 (81%) patients and in all 37 (100%) cases with PB myeloid progenitor cell count of 0.1 × 10⁹ L^-1 or above (p = 0.02). Twenty-two patients had concomitant PB and bone marrow (BM) cytogenetic studies; 6 showed similarly abnormal findings in both BM and PB. In another 2 cases, results were abnormal in BM but normal in PB; the opposite was seen in 1 case. These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice.

Original language	English (US)
Pages (from-to)	1597-1600
Number of pages	4
Journal	Leukemia Research
Volume	32
Issue number	10
DOIs	https://doi.org/10.1016/j.leukres.2007.12.005
State	Published - Oct 2008

Keywords

Myelofibrosis
Peripheral blood and bone marrow cytogenetics

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2007.12.005

Cite this

@article{9774364883f94a309b4a91c57c16bfef,

title = "Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies",

abstract = "Among 59 consecutive patients with myelofibrosis (MF) in whom peripheral blood (PB) cytogenetic studies were performed, at least two analyzable metaphases (median 20, range 2-31) were obtained in 49 (81%) patients and in all 37 (100%) cases with PB myeloid progenitor cell count of 0.1 × 109 L-1 or above (p = 0.02). Twenty-two patients had concomitant PB and bone marrow (BM) cytogenetic studies; 6 showed similarly abnormal findings in both BM and PB. In another 2 cases, results were abnormal in BM but normal in PB; the opposite was seen in 1 case. These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice.",

keywords = "Myelofibrosis, Peripheral blood and bone marrow cytogenetics",

author = "Kebede Hussein and Ketterling, {Rhett P.} and Dewald, {Gordon W.} and {Van Dyke}, {Daniel L.} and Ruben Mesa and Hanson, {Curtis A.} and Ayalew Tefferi",

year = "2008",

month = oct,

doi = "10.1016/j.leukres.2007.12.005",

language = "English (US)",

volume = "32",

pages = "1597--1600",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Peripheral blood cytogenetic studies in myelofibrosis

T2 - Overall yield and comparison with bone marrow cytogenetic studies

AU - Hussein, Kebede

AU - Ketterling, Rhett P.

AU - Dewald, Gordon W.

AU - Van Dyke, Daniel L.

AU - Mesa, Ruben

AU - Hanson, Curtis A.

AU - Tefferi, Ayalew

PY - 2008/10

Y1 - 2008/10

N2 - Among 59 consecutive patients with myelofibrosis (MF) in whom peripheral blood (PB) cytogenetic studies were performed, at least two analyzable metaphases (median 20, range 2-31) were obtained in 49 (81%) patients and in all 37 (100%) cases with PB myeloid progenitor cell count of 0.1 × 109 L-1 or above (p = 0.02). Twenty-two patients had concomitant PB and bone marrow (BM) cytogenetic studies; 6 showed similarly abnormal findings in both BM and PB. In another 2 cases, results were abnormal in BM but normal in PB; the opposite was seen in 1 case. These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice.

AB - Among 59 consecutive patients with myelofibrosis (MF) in whom peripheral blood (PB) cytogenetic studies were performed, at least two analyzable metaphases (median 20, range 2-31) were obtained in 49 (81%) patients and in all 37 (100%) cases with PB myeloid progenitor cell count of 0.1 × 109 L-1 or above (p = 0.02). Twenty-two patients had concomitant PB and bone marrow (BM) cytogenetic studies; 6 showed similarly abnormal findings in both BM and PB. In another 2 cases, results were abnormal in BM but normal in PB; the opposite was seen in 1 case. These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice.

KW - Myelofibrosis

KW - Peripheral blood and bone marrow cytogenetics

UR - http://www.scopus.com/inward/record.url?scp=44749093672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44749093672&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.12.005

DO - 10.1016/j.leukres.2007.12.005

M3 - Article

C2 - 18241918

AN - SCOPUS:44749093672

SN - 0145-2126

VL - 32

SP - 1597

EP - 1600

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this